ALNYAlnylam Pharmaceuticals, Inc.

$232.57-49% 1Y

Is it safe?

Mixed

Solid, nothing alarming. Safe balance sheet, some accounting flags, quality moderate.

1 good, 4 neutral, 1 without data
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksGrey zone

Some accounting flags, worth a closer look Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality5 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$399K

Insiders were net sellers (-$399K, 90 days to Oct 8, 2026), selling is often routine.

Drawdown risk44% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -60% · now 53% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market
Max drawdownmiddle of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can ALNY take a bad year?

The deepest fall in ALNY's price history on file is −60%; it is 53% below its high today.

5.44

Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one

Interest cover
2.18×

Interest cover · operating profit covers the interest bill, with room to spare

Annualised volatility
44%

Annualised volatility · roughly twice as jumpy as the market

Worst drawdown on file
−60%

Worst drawdown on file · −53% today

Details›
Cash and short-term investments
$2.91B
EBITDA, trailing twelve months
$557M
Operating profit, trailing twelve months
$502M
Annualised volatilitytwo years of daily moves
44%
Worst drawdown on file
−60%
Below its 52-week high
53%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

On our screens:R&D leaders